Accéder au contenu
Merck

Anti-IL-12/23 p40 antibody attenuates chronic graft-versus-host disease with lupus nephritis via inhibiting Tfh cell in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (2020-06-25)
Yue Gao, Yu Zeng, Wenyao Xue, Yucong Chen, Qianwen Li, Zhengying Bian, Lei Tang, Tiejun Tang, Cong Chen, Xiangdong Gao, Wei Guo
RÉSUMÉ

Systemic lupus erythematosus (SLE) is an autoimmune disease that is mainly caused by excessive accumulation of autoantibodies that target autoantibodies such as nucleic acids. T helper (Th) cell have been associated with the development of SLE. Typically, different subsets of Th cells secrete various cytokines to regulate the disease progression. IL-12 and IL-23 participate in the differentiation and activation of multiple Th cell subsets, including Th1, Th2, Th9, Th17, regulatory T (Treg) and follicular helper T (Tfh) cells. Because of the signature p40 subunit shared by IL-12 and IL-23, blocking IL-12/IL-23 signaling may interfere the differentiation of Th cell and directly inhibit the secretion of proinflammatory cytokines. In this study, we examined the effects of anti-IL-12/23 p40 antibody on chronic graft-versus-host disease with lupus nephritis, and found that the therapeutic effectiveness was mediated through the inhibition of Tfh cell in mice. Moreover, anti-IL-12/23 p40 antibody inhibited human Tfh cell differentiation in vitro. These results strongly suggest that Tfh cell contribute to the pathogenesis of SLE, and the neutralization of IL-12/IL-23 signaling during Tfh cell differentiation may be critical for the treatment of SLE.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Protease Inhibitor Cocktail, Animal Component Free, for use with mammalian cell and tissue extract, DMSO solution